logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Eisai Inc. drugs

    FiltersReset Filters
    7 results

    • aricept - donepezil hydrochloride tablet, film coated

      (Donepezil Hydrochloride)
      Eisai Inc.

    • banzel

      (rufinamide)
      Eisai Inc.
      Usage: BANZEL is indicated as an adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome in pediatric patients aged 1 year and older, as well as in adults.

    • dayvigo

      (lemborexant)
      Eisai Inc.
      Usage: DAYVIGO is indicated for the treatment of adult patients with insomnia, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance.

    • fycompa

      (perampanel)
      Eisai Inc.
      Usage: FYCOMPA is indicated for treating partial-onset seizures in patients aged 4 and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 and older.

    • halaven

      (eribulin mesylate)
      Eisai Inc.
      Usage: HALAVEN is indicated for treating metastatic breast cancer in patients who have received at least two prior chemotherapy regimens, including anthracyclines and taxanes, and for unresectable or metastatic liposarcoma in patients previously treated with an anthracycline-containing regimen.

    • lenvima

      (Lenvatinib)
      Eisai Inc.
      Usage: LENVIMA is indicated for treating adult patients with radioactive iodine-refractory differentiated thyroid cancer, advanced renal cell carcinoma (in combination with pembrolizumab or everolimus), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (with pembrolizumab) not amenable to curative surgery or radiation.

    • leqembi

      (lecanemab)
      Eisai Inc.
      Usage: LEQEMBI is indicated for treating Alzheimer's disease in patients with mild cognitive impairment or mild dementia, as these were the groups studied in clinical trials.